Cytonus Therapeutics, Inc.
Cytonus Therapeutics is pioneering the convergence of artificial intelligence and synthetic biology to revolutionize drug development and delivery. The company challenges the high failure rates of traditional and precision medicines by developing next-generation therapeutics that are both highly effective and safe. Their mission is to create pragmatic shifts in how drugs are designed and administered, focusing on precision, safety, and efficacy to improve patient outcomes.
Cytonus Therapeutics, Inc.
What We Do
A proprietary, functional cell-like synthetic entity (without a nucleus) designed for targeted drug delivery. Cargocytes are engineered using AI and synthetic biology to deliver and produce therapeutic payloads (biologic drugs) directly at disease sites, such as tumors or difficult-to-access organs, minimizing systemic toxicity and maximizing efficacy.
HIEstem (TM)
HIEstem, is a regenerative medicine therapy for the treatment of Intraventricular Hemorrhage of Newborns (IVH) and is Phase 2/3 clinical trial ready. HIEstem is being tested for Ischemic Stoke and Traumatic Brain Injury (TBI) as the insults and mechanisms of damage are clinically identical to IVH.
Contract Manufacturer
Cytonus currently offers CMO-like services based on proriatary products developed by the company including customized Cargocytes, Clinical Grade Mesenchymal Stem Cells, Immortalized Cell-lines, and Exosomes.
Digital Health Technologies
Drugs
Key People
News & Updates
Cytonus has received funding from eight grants and support from industry-leading biotech investors, reflecting strong confidence in their innovative approach and technology.
An article detailing the science and innovation behind Cytonus' targeted drug delivery platform, highlighting the transition from conceptual science to real-world application.